Cargando…
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
Homologous recombination deficiency (HRD) leads to DNA double‐strand breaks and can be exploited by the use of poly (ADP‐ribose) polymerase (PARP) inhibitors to induce synthetic lethality. Extending the original therapeutic concept, the role of HRD is currently being investigated in clinical trials...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161338/ https://www.ncbi.nlm.nih.gov/pubmed/35384413 http://dx.doi.org/10.1002/cjp2.271 |
_version_ | 1784719462894665728 |
---|---|
author | Budczies, Jan Kluck, Klaus Beck, Susanne Ourailidis, Iordanis Allgäuer, Michael Menzel, Michael Kazdal, Daniel Perkhofer, Lukas Kleger, Alexander Schirmacher, Peter Seufferlein, Thomas Stenzinger, Albrecht |
author_facet | Budczies, Jan Kluck, Klaus Beck, Susanne Ourailidis, Iordanis Allgäuer, Michael Menzel, Michael Kazdal, Daniel Perkhofer, Lukas Kleger, Alexander Schirmacher, Peter Seufferlein, Thomas Stenzinger, Albrecht |
author_sort | Budczies, Jan |
collection | PubMed |
description | Homologous recombination deficiency (HRD) leads to DNA double‐strand breaks and can be exploited by the use of poly (ADP‐ribose) polymerase (PARP) inhibitors to induce synthetic lethality. Extending the original therapeutic concept, the role of HRD is currently being investigated in clinical trials testing immune checkpoint blockers alone or in combination with PARP inhibitors, but the relationship between HRD and immune cell context in cancer is incompletely understood. We analyzed the association between immune cell composition, gene expression, and HRD in 9,041 tumors of 32 solid cancer types from The Cancer Genome Atlas (TCGA). The numbers of genomic scars were quantified by the HRD sum score (HRDsum) including loss of heterozygosity, large‐scale state transitions, and telomeric allelic imbalance. The T‐cell inflamed gene expression profile correlated weakly, but significantly positively, with HRDsum across cancer types (ρ = 0.17). Within individual cancer types, a significantly positive correlation was observed only in breast cancer, ovarian cancer, and four other cancer types, but not in the remaining 26 cancer types. HRDsum and tumor mutational burden (TMB) correlated significantly positively across cancer types (ρ = 0.42) and within 18 cancer types. HRDsum and a proliferation metagene correlated significantly positively across cancer types (ρ = 0.52) and within 20 cancer types. Mismatch repair deficiency and HRD as well as proofreading deficiency showed a high level of exclusivity. High HRD scores were associated with an immunologically activated tumor microenvironment only in a minority of cancer types. Our data favor the combination of genetic markers, complex genomic markers (including HRDsum and TMB), and other molecular markers (including proliferation scores) for a precise and comprehensive read‐out of the tumor biology and an individually tailored treatment. |
format | Online Article Text |
id | pubmed-9161338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91613382022-06-04 Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types Budczies, Jan Kluck, Klaus Beck, Susanne Ourailidis, Iordanis Allgäuer, Michael Menzel, Michael Kazdal, Daniel Perkhofer, Lukas Kleger, Alexander Schirmacher, Peter Seufferlein, Thomas Stenzinger, Albrecht J Pathol Clin Res Original Articles Homologous recombination deficiency (HRD) leads to DNA double‐strand breaks and can be exploited by the use of poly (ADP‐ribose) polymerase (PARP) inhibitors to induce synthetic lethality. Extending the original therapeutic concept, the role of HRD is currently being investigated in clinical trials testing immune checkpoint blockers alone or in combination with PARP inhibitors, but the relationship between HRD and immune cell context in cancer is incompletely understood. We analyzed the association between immune cell composition, gene expression, and HRD in 9,041 tumors of 32 solid cancer types from The Cancer Genome Atlas (TCGA). The numbers of genomic scars were quantified by the HRD sum score (HRDsum) including loss of heterozygosity, large‐scale state transitions, and telomeric allelic imbalance. The T‐cell inflamed gene expression profile correlated weakly, but significantly positively, with HRDsum across cancer types (ρ = 0.17). Within individual cancer types, a significantly positive correlation was observed only in breast cancer, ovarian cancer, and four other cancer types, but not in the remaining 26 cancer types. HRDsum and tumor mutational burden (TMB) correlated significantly positively across cancer types (ρ = 0.42) and within 18 cancer types. HRDsum and a proliferation metagene correlated significantly positively across cancer types (ρ = 0.52) and within 20 cancer types. Mismatch repair deficiency and HRD as well as proofreading deficiency showed a high level of exclusivity. High HRD scores were associated with an immunologically activated tumor microenvironment only in a minority of cancer types. Our data favor the combination of genetic markers, complex genomic markers (including HRDsum and TMB), and other molecular markers (including proliferation scores) for a precise and comprehensive read‐out of the tumor biology and an individually tailored treatment. John Wiley & Sons, Inc. 2022-04-05 /pmc/articles/PMC9161338/ /pubmed/35384413 http://dx.doi.org/10.1002/cjp2.271 Text en © 2022 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Budczies, Jan Kluck, Klaus Beck, Susanne Ourailidis, Iordanis Allgäuer, Michael Menzel, Michael Kazdal, Daniel Perkhofer, Lukas Kleger, Alexander Schirmacher, Peter Seufferlein, Thomas Stenzinger, Albrecht Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
title |
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
title_full |
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
title_fullStr |
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
title_full_unstemmed |
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
title_short |
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
title_sort | homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161338/ https://www.ncbi.nlm.nih.gov/pubmed/35384413 http://dx.doi.org/10.1002/cjp2.271 |
work_keys_str_mv | AT budcziesjan homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT kluckklaus homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT becksusanne homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT ourailidisiordanis homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT allgauermichael homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT menzelmichael homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT kazdaldaniel homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT perkhoferlukas homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT klegeralexander homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT schirmacherpeter homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT seufferleinthomas homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes AT stenzingeralbrecht homologousrecombinationdeficiencyisinverselycorrelatedwithmicrosatelliteinstabilityandidentifiesimmunologicallycoldtumorsinmostcancertypes |